Table 2. Most Common Grade 3 or 4 Adverse Events Possibly, Probably, or Definitely Associated With Protocol Treatment.

All grade ≥3 events	No. (%)			P value^a
All grade ≥3 events	All patients	Gemcitabine/nab-paclitaxel/NPC-1C (n = 38)	Gemcitabine/nab-paclitaxel (n = 40)	P value^a
Anemia	19 (24)	15 (39)	4 (10)	.003
Fatigue	6 (8)	5 (13)	1 (3)	.10
Liver function test^b	8 (10)	6 (16)	2 (5)	.15
Lymphopenia	6 (8)	3 (8)	3 (8)	>.99
Neutropenia	26 (33)	14 (37)	12 (30)	.63
Peripheral neuropathy	4 (5)	1 (3)	3 (8)	.62
Thrombocytopenia	20 (26)	12 (32)	8 (20)	.30

^{^a}

P value comparing gemcitabine plus nab-paclitaxel and NPC-1C vs gemcitabine plus nab-paclitaxel.

^{^b}

Liver function test defined as an abnormality in aspartate transaminase, alanine transaminase, or total bilirubin.